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Abstract
Background Clinical inertia, the failure of physicians to
initiate or intensify therapy when indicated, is a major
problem in the management of hypertension and may be
more prevalent in elderly patients. Overcoming clinical
inertia requires understanding its causes and evaluating
certain factors, particularly those related to physicians.
Objective The objective of our study was to determine
the rate of clinical inertia and the physician-reported rea-
sons for it.
Methods An observational, cross-sectional, multi-center
study was carried out in a primary care setting. We
included 512 physicians, with a consecutive sampling of
1,499 hypertensive patients with clinical inertia.
Main Outcome Measure Clinical inertia was defined
when physicians did not modify treatment despite knowing
that the therapeutic target had not been reached. Clinical
inertia was considered to be justified (JCI) when physicians
provided an explanation for not intensifying treatment and
as not justified (nJCI) when no reasons were given.
Results JCI was observed in 30.1 % (95 % CI 27.8–32.4)
of patients (n = 451) and nJCI in 69.9 % (95 % CI
67.6–72.2) (n = 1,058). JCI was associated with higher
blood pressure (BP) values (both systolic and diastolic) and
diabetes (p = 0.012) than nJCI. nJCI was associated with
patients having an isolated increase of systolic or diastolic
or high borderline BP values or cardiovascular disease.
Conclusion Physicians provided reasons for not intensi-
fying treatment in poorly controlled patients in only 30 %
of instances. Main reasons for not intensifying treatment
were borderline BP values, co-morbidity, suspected white
coat effect, or perceived difficulty achieving target. nJCI
was associated with high borderline BP values and car-
diovascular disease.
1 Introduction
More than one-third of patients receiving treatment for
hypertension in the US have uncontrolled blood pressure
(BP) [1]. BP control rates for hypertension fall far short of the
expected goals, especially in older hypertensive patients
with high systolic BP (SBP) or isolated systolic hypertension
[1–3]. In 2001, Phillips et al. [4] defined clinical inertia as
failure by physicians to initiate or intensify clinical therapy
when indicated, and the Joint National Committee (JNC)-
VII report accepted clinical inertia as an important reason for
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the lack of adequate BP control in hypertensive patients [5].
Overcoming clinical inertia requires an understanding of its
causes [6] and evaluating the associated variables, particu-
larly those related to physician attitudes (50 %), patient-
related characteristics (30 %), and the level of healthcare
(20 %) [4, 7–9]. A study from our group conducted in
hypertensive patients aged [40 years found that clinical
inertia was present in one of every three cases of high BP
[10]. Amongst the variables associated with clinical inertia,
co-morbidity, which requires lower BP goals, was the most
important [10]. Several studies [11–14] have shown that
clinicians do not consider small elevations above goal BP to
be a cause for concern. But reasons for not intensifying
treatment have not been widely explored in ageing patients.
Therefore, we designed a new study to explore clinical
inertia in aged patients in Spain. Previously, we have
reported [15] the magnitude of clinical inertia to be 42.1 % in
poorly controlled, aged hypertensive patients with several
associated factors (older age, lack of co-morbidity, and being
seen at a primary care center). In this study, we analyze
physicians’ self-reported rationale for clinical inertia.
2 Material and Methods
We undertook an observational, cross-sectional, multicen-
ter study involving ambulatory patients from primary care
centers and hospital hypertension units in Spain. We fol-
lowed the BP recommendations from the seventh report of
the JNC [5] and the European Task Force for the Man-
agement of Arterial Hypertension [16]. Our participant
physicians adopted a conservative attitude of not modify-
ing treatment despite knowing that the therapeutic target
had not been reached [4]. Clinical inertia was classified as
‘justified’ when a reason was given and ‘not justified’ when
physicians marked the option ‘no reasons to give’. A total
of 512 physicians participated in the study between Feb-
ruary and June 2007. Information about the problem of
clinical inertia and the guideline-recommended goals [4, 5,
8] was sent to physicians, who were selected in a random
manner from a primary care physicians group from the
Spanish Society of Arterial Hypertension. They come from
different regions in Spain. Of the physicians who were
invited to participate, 8 % declined.
Physicians were informed about other causes of poor BP
control, such as white coat hypertension, therapeutic non-
compliance, incorrect BP measurement, or interactions
with other drugs in order to assist them in assigning a
reason for not changing treatment.
Using consecutive sampling, each physician included
8–12 poorly controlled hypertensive patients who came for
a routine visit. The inclusion criteria were as follows:
hypertensive patients diagnosed according to the 2003
criteria of the European Societies of Hypertension and
Cardiology, [17] providing signed informed consent, either
sex, aged C50 years, having arterial hypertension diag-
nosed at least 6 months previously, and receiving stable
drug treatment for at least 4 weeks. Patients were excluded
if they had any severe mental or social problem or if they
were hypertensive patients with a very low life expectancy.
This report is the continuation of a wider study about
clinical inertia. The first paper [15] analyzed the magnitude
of clinical inertia and its associated factors. The sample
size was calculated to be 4,860 hypertensive patients [15].
For this study, we included only those patients who were
classified as having clinical inertia (n = 1,499).
Patient characteristics included those related to the 2007
prognostic stratification guidelines of cardiovascular risk
[16]. We recommended BP be measured by physicians
with the usual device, in accordance with standard clinical
practice guidelines [5, 16]. At the control visit, the BP was
recorded twice, with an interval of 5 minutes, with the
patient rested and seated. If the difference between these
two measurements was [5 mmHg, a third measurement
was taken. The average of the two or three measurements
was considered to be the BP for the purposes of therapeutic
decision making. Cardiovascular risk was classified into
four categories: low (\15 %), moderate (15–19 %), high
(20–30 %), and very high ([30 %) [11], and analyzed by
comparing a ‘high’ plus ‘very high’ risk with a ‘low’ plus
‘moderate’ cardiovascular risk.
The type of treatment was evaluated as monotherapy,
fixed-dose combination therapy (two active components in
one tablet), and free-dose combination therapy (two or
more free-dose tablets). Healthcare setting was evaluated
according to whether the ambulatory patient was seen in
primary care centers or hospital hypertension units. Poor
BP control was defined by clinical guidelines [5, 16] as
SBP C140 mmHg and/or diastolic BP (DBP) C90 mmHg;
in patients with diabetes or established cardiovascular or
renal disease, the values were SBP C130 mmHg and/or
DBP C80 mmHg. The reasons offered to physicians to
explain why they did not intensify treatment, were as fol-
lows: (i) accepting small elevations above goal BP as
adequate; (ii) being unable to exclude the possibility of
white-coat hypertension; (iii) perceived difficulty in man-
aging the BP due to the clinical condition of the patient;
(iv) perceived difficulty in achieving the guideline goals;
(v) not being able to rule out noncompliance with non-
pharmacological measures; (vi) patient already taking ‘‘a
lot of drugs’’ for BP control; (vii) patients would not be
able to tolerate intensification of drug therapy; (viii)
hypertensive patients in whom it was impossible to reduce
the BP further; (ix) not being able to rule out noncompli-
ance with drugs; (x) treatment indicated by specialists; (xi)
refractory hypertension; (xii) patient didn’t want to take
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any more pills; (xiii) impossible to be sure BP has been
correctly measured; (xiv) interaction with other drugs; (xv)
low cardiovascular risk; and (xvi) other reasons. More than
one reason could be chosen.
The statistical analysis was done with SPSS Statistics
17.0 for Windows (SPSS Inc., Chicago, IL, USA) and
STATA (StataCorp LP, College Station, TX, USA) pro-
grams. A univariate analysis was conducted and the chi-
squared (v2) test was used in bivariate analysis to compare
qualitative variables and the Student t test to compare the
qualitative variable with another quantitative variable. The
95 % confidence intervals (CIs) were calculated for the
most important variables.
Binomial logistic regression multivariate analysis,
adjusted for physician, was also performed, with clinical
inertia considered as the dependent variable. Data were
collected using a personal digital assistant computer and
were sent from the physician’s office to the reception
center and the statistics agency for analysis of both quality
control and statistics.
The study followed the EU recommendations and
norms of Good Clinical Practice. Any personal data
necessary for the study was treated in accordance with
the Spanish Royal Decree 1720 of 21 December 2007,
related to the requirements for data protection and
confidentiality.
3 Results
Table 1 shows characteristics of included hypertensive
patients. In patients with clinical inertia, the mean age was
66.0 ± 11.9 years, the mean SBP was 140.2 ± 12.4 mmHg,
and the mean DBP was 81.1 ± 8.9 mmHg; 51.8 % had
known cardiovascular disease (i.e. secondary prevention),
42.8 % had diabetes, 72.3 % were taking some type of com-
bination therapy, and 90.3 % (95 % CI 88.8–91.8) had high
cardiovascular risk.
Physicians gave a reason for not changing treatment
despite poor BP control in 30.1 % (95 % CI 27.8–32.4) of
patients (n = 451), and no reasons were given in 69.9 %
(95 % CI 67.6–72.2) of patients (n = 1,048). No signifi-
cant differences in cardiovascular risk were found between
the justified and unjustified clinical inertia groups (89.1 vs.
90.8 %; p [ 0.05).
Table 2 shows the reasons provided by physicians to
explain clinical inertia. Main reasons were small elevations
above goal BP deemed not relevant by the clinician
(27.3 %); presence of co-morbidity made BP more difficult
to manage (26.8 %); and suspicion of white coat hyper-
tension (25.7 %). Average number of reasons was
1.84 ± 0.78 (95 % CI 1.81–1.87). Two reasons were given
by 53.9 % of physicians.
Table 3 shows a comparison between instances of
justified and unjustified clinical inertia. According to
multivariate analysis, the variables associated with justi-
fied clinical inertia were higher BP values (both SBP and
DBP; p \ 0.001 for both) and presence of diabetes
(p = 0.012). No differences were found for sex, type of
drug therapy, or treatment setting. The factors associated
with unjustified clinical inertia were secondary prevention
(to have cardiovascular disease; p \ 0.001) and an iso-
lated increase of SBP or DBP or high borderline BP
values (p \ 0.001).
4 Discussion
Physicians gave no reason to explain why they did not
intensify therapy in seven of every ten hypertensive
patients with poorly controlled BP. An explanation for
clinical inertia was only available for 30 % of patients.
One of the main reasons given for failure to intensify
therapy was high borderline BP values acceptable for the
patient’s clinical situation, i.e. meaning that small eleva-
tions above goal BP were not a cause of concern for cli-
nicians (Table 2).
There was some obvious overlap in reasons for clinical
inertia provided by physicians, e.g. ‘difficult to manage due
to co-morbidities’ and ‘difficult to achieve BP goals’ and
‘impossible to reduce BP any further’ and ‘patient with co-
morbidities in whom good BP control is more difficult to
achieve’ and ‘refractory hypertension’. These reasons
probably account for patient-related or disease-related
conditions that make the decision to intensify treatment
difficult. There is also overlap between ‘white coat
Table 1 Patient characteristics
Characteristic Inertia (n = 1,499)
[% (95 % CI)]
Male 53.7 (51.2–56.2)
Type 2 diabetes mellitus 42.8 (40.3–45.3)
Obesity 42.9 (40.4–45.4)
Hypertension treatment with C2 drugs 72.3 (70.0–74.6)
Primary care 44.9 (42.4–47.4)
Secondary prevention 51.8 (49.3–54.3)
Isolated systolic hypertension 48.2 (45.7–50.7)
Isolated diastolic hypertension 8.9 (7.4–10.4)
Joint increase of SBP and DBP 42.9 (40.4–45.4)
Age (years)a 66.0 ± 11.9 (65.4–66.6)
SBP (mmHg)a 140.2 ± 12.4 (141.4–142.6)
DBP (mmHg)a 81.1 ± 8.9 (80.7–81.6)
a Figures presented as mean ± SD (95 % CI)
CI confidence interval, DBP diastolic blood pressure, SBP systolic
blood pressure, SD standard deviation
Clinical Inertia in Treating Hypertension 215
Author's personal copy
hypertension’ and ‘BP measurement could be incorrect’,
i.e. implying BP measurement-related causes.
Justified clinical inertia was associated with higher BP
values (both SBP and DBP) and diabetes. Older age was of
borderline statistical significance (see Table 3).
As recent recommendations of BP targets in elderly
patients are less aggressive [18] than previous goals [5, 16],
the magnitude of this inertia is clearly reduced. Recom-
mendations could vary from one guideline to another [5,
16, 18] and, consequently, cause variations in the measured
prevalence of clinical inertia, as it depends on guideline
standards. These differences between various guidelines
could also contribute to physicians’ distrust of the optimal
guideline-recommended BP goals.
This is, in fact, very common in clinical practice. If we
adjust the prevalence according to age, we see that 75 % of
hypertensive women and 65 % of hypertensive men are
aged [60 years [19] and that three of every four patients
with known cardiovascular disease have hypertension [20].
Studies [21, 22] indicate that clinical inertia can have an
adverse impact on clinical outcomes because hypertensive
patients need early BP control and any delay is associated
with an increased incidence of cardiovascular events.
Long-term follow-up studies are needed to measure the
impact of clinical inertia on clinical outcomes in hyper-
tensive patients.
Recent reappraisal of guidelines [18] has led to less
aggressive BP targets in special populations such as the
elderly and those with diabetes. However, at the time this
study was undertaken, these recommendations had not
been published. It would be of interest to design a new
study to analyze the impact of these new targets on clinical
inertia.
Despite less aggressive BP targets, we believe that it
will still be hard to overcome clinical inertia. In our study,
physicians did not intensify pharmacological treatment as
they suspected other reasons for poor BP control, such as
white coat hypertension, patient’s non-adherence, or wait-
ing for improvement of BP control with non-pharmaco-
logical interventions (e.g. diet and exercise). These reasons
are sometimes difficult to discount in real clinical practice.
Other concerns expressed by physicians indicate a cer-
tain resistance to tackling clinical inertia, i.e. patients with
‘high-borderline’ BP could be accepted as being well
controlled; that the co-morbid conditions are difficult to
manage; that there is difficulty achieving the guideline-
recommended goals; that some patients are fragile and will
not be able to tolerate intensification of therapy; that
adherence is more difficult when taking multiple antihy-
pertensive medications; or that it is impossible to reduce
the BP any further, especially SBP.
The analysis of the reasons provided by physicians also
suggests that it will be challenging to overcome this clin-
ical inertia, as managing these patients is difficult because
they are older and have multiple disorders requiring com-
plex therapy. This clinical inertia could be associated with
medical errors [6, 8].
The age-related arterial hardening and aortic stiffness
seen in many elderly hypertensive patients makes it more
difficult to control the SBP component [1–3, 23]. In this
situation, physicians need to be educated that achieving BP
goals is likely to require combination therapy with three or
more antihypertensive drugs, given the likely multifactorial
origin of the hypertension [1, 24, 25].
In the study by Ho et al., only 9.8 % of physicians
admitted to clinical inertia when they suspected noncom-
pliance in their hypertensive patients [26]. Ambulatory BP
monitoring is recommended in poorly controlled, high-risk
hypertensive patients [27]. The usual attitude of
Table 2 Reasons for failure to intensify therapy despite poor blood
pressure control
Reasons reported by physicians (n) (%) 95 %
confidence
limits
High borderline values acceptable for
patient’s clinical situation
123 27.3 23.2–31.4
Difficult to manage due to clinical
situation (co-morbidities)
121 26.8 22.7–30.9
White coat effect suspected 116 25.7 21.7–29.7
Difficult to achieve guideline goals 93 20.6 16.9–24.3
Noncompliance with prescribed diet/
exercise suspected
74 16.4 13.0–19.8
Impossible to reduce BP further 55 12.2 9.2–15.2
Already taking too many BP drugs 52 11.5 8.6–14.4
Patient easily decompensate (side
effects)
46 10.2 7.4–13.0
Noncompliance with drugs suspected 44 9.8 7.1–12.5
Treatment indicated by specialists 28 6.2 4.0–8.4
Refractory hypertension 18 4.0 2.2–5.8
Patient does not wish to take more
pills
16 3.6 1.9–5.3
BP measurement could be incorrect 10 2.2 0.8–3.6
Patient with co-morbidities in whom
good BP control is more difficult to
achieve
8 1.8 0.6–3.0
Interaction with other drugs 6 1.3 0.2–2.4
Cardiovascular risk low despite
uncontrolled BP
5 1.1 0.1–2.1
Other reasons 15 3.3 1.7–4.9
Subtotal (reasons givena) 451 30.1 (27.8–32.4)
No reasons givenb 1,048 69.9 (67.6–72.2)
Total 1,499 100.0
a Justified inertia (n = 451 patients)
b Unjustified inertia (n = 1,048 patients)
BP blood pressure
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physicians is to make a new appointment in the hope that
patient behavior will change (i.e. improved adherence to
medication, better compliance with prescribed diet or
exercise) rather than to intensify medication. However,
patient behavior seldom changes and, therefore, these
patients attend the office more often than patients with
good BP control, but there is still a delay in treatment
change [28, 29]. It must be that a white coat effect and
noncompliance are difficult to rule out in real clinical
practice. Furthermore, clinical inertia is common in older
patients with diabetes and hypertension with poor BP
control [30].
The mean BP values shown in Table 1 are close to
normal. In our previous study, [15] we showed how inertia
is related to small elevations above goal BP, and that may
explain why the mean BP is low, despite all patients being
poorly controlled (Table 1). Nearly 50 % of patients had
isolated SBP with normal DBP values.
Unjustified inertia was associated with patients having
an isolated increase of SBP or DBP or high-borderline BP
values, or existing cardiovascular disease. Inertia was
higher in poorly controlled patients with borderline BP
values. Patients with unjustified inertia had BP values
slightly lower than did patients with justified inertia
(Table 3). Physicians did not justify inertia in patients with
BP only slightly above the normal values because they
probably thought that the goal had been achieved. For
higher BP values, physicians may have felt uncomfortable
about not being able to provide a justification for not
changing treatment.
Because the clinical consequences may be more severe,
it is even more difficult to accept clinical inertia in patients
Table 3 Bivariate and multivariate analyses of the patient and healthcare-level predictive factors according to whether the inertia was or was
not justified
Variables Inertia not justified
(n = 1,048) [n (%)]
Inertia justified
(n = 451) [n (%)]
p-Value Bivariate analysis
[OR (95 % CI)]
p-Value Multivariate
analysis [OR (95 %
CI)]
p-Value
Sex
Men 588 (56.1) 21.8 (48.3) 0.006 1.37 (1.09–1.71) 0.006 1.16 (0.90–1.49) 0.260
Women 460 (43.9) 233 (51.7)
Agea (years) 65.7 ± 11.6 66.7 ± 12.4 0.138 0.99 (0.98–1.01) 0.237 0.99 (0.98–1.00) 0.089
SBPa (mmHg) 138.8 ± 10.5 149.6 ± 13.2 \0.001 0.92 (0.91–0.94) \0.001 0.93 (0.92–0.95) \0.001
DBPa (mmHg) 79.6 ± 8.1 84.6 ± 9.6 \0.001 0.93 (0.92–0.95) \0.001 0.95 (0.93–0.97) \0.001
Diabetes mellitus 436 (41.6) 205 (45.5) 0.167 0.85 (0.66–1.10) 0.226 0.69 (0.51–0.92) 0.012
Secondary prevention 583 (55.6) 193 (42.8) \0.001 1.68 (1.29–2.19) \0.001 1.20 (0.88–1.62) 0.250
2.02 (1.40–2.80)b \0.001 2.03 (1.43–2.89)b \0.001
Monotherapy 283 (27.0) 133 (29.5) 0.002 1.43 (1.09–1.89)c 0.011 1.24 (0.89–1.74)c 0.208
FixDCT 409 (39.0) 134 (29.7) 0.91 (0.66–1.26)d 0.564 0.86 (0.58–1.28)d 0.455
FrDCT 356 (34.0) 184 (40.8)
Care level
Specialized 603 (57.5) 223 (49.5) 0.004 1.39 (0.98–1.95) 0.062 1.09 (0.74–1.62) 0.662
Primary 445 (42.5) 228 (50.6)
Obesity 434 (41.4) 209 (46.3) 0.077 0.82 (0.65–1.03) 0.086 0.91 (0.69–1.21) 0.522
Sedentary lifestyle 499 (47.6) 245 (54.3) 0.017 0.76 (0.60–0.97) 0.030 0.84 (0.63–1.13) 0.247
Elevated BP category
Isolated systolic 546 (52.1) 177 (39.3) \0.001 2.05 (1.67–2.51)b \0.001 2.51 (1.61–3.93)b \0.001
Isolated diastolic 115 (11.0) 18 (4.0)
Joint increase of both
(systolic and diastolic)
387 (36.9) 256 (56.8)
a Mean ± standard deviation
b Significant variables when the BP values were introduced into the multivariate analysis by category
c Comparison between monotherapy and FixDCT
d Comparison between monotherapy and FrDCT
BP blood pressure, CI confidence interval, DBP diastolic BP, FixDCT fixed-dose combination therapy, FrDCT free-dose combination therapy,
OR odds ratio, SBP systolic BP
x  r: mean ± standard deviation
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with existing cardiovascular disease. However, this fact has
been described in Spain and other countries [15] and will
need specific effort to be addressed.
Phillips et al. [4] focused the problem of clinical inertia
only on physicians. So, clinical inertia could be due to three
reasons: overestimation of care provided; use of ‘soft’
reasons to avoid intensification of therapy; and lack of
education, training, and practice organization aimed at
achieving therapeutic goals. On the other hand, Okonofua
et al. [7] established that not only physicians but charac-
teristics of both patients and healthcare systems can influ-
ence clinical inertia.
Our results based on physicians’ perceptions about the
reasons for not intensifying treatment in poorly controlled
hypertensive patents identify the characteristics of the
patient as the most important reason (Table 2). Charac-
teristics of the healthcare system are also related (Table 2).
Some other reasons given could be described as ‘soft rea-
sons’ to avoid intensification of therapy (i.e. impossible to
reduce BP further) or could be related to lack of education,
training, and practice organization aimed at achieving
therapeutic goals (e.g. difficult to achieve guideline goals,
acceptable cardiovascular risk despite uncontrolled BP).
Importantly, almost 70 % of physicians marked the
answer ‘No reason to give’. It would be useful to know
why these physicians did not provide a reason, but we need
another study to answer this question. Perhaps we could
achieve this by using a more qualitative than quantitative
methodology (i.e. focus group). This attitude could be
associated with overestimation of care provided, defined by
Phillips et al. [4], but also with patient characteristics,
suggested by Okonofua et al. [7].
In patients with diabetes, the dominant reasons for
failure to intensify therapy were the perception by the
provider that BP control was improving (34 %) or the
belief that the patient was not compliant with diet or
medications (25 %), and no reasons were given for 18 % of
patients [31]. Ogedegbe [32] found one of the major rea-
sons for clinical inertia in hypertension was clinicians’ use
of soft reasons to avoid treatment intensification by
adopting a ‘wait until next visit’ approach in response to
patients’ excuses. In another study [33], participants were
providers who cared for 1,017 patients with uncontrolled
hypertension receiving a single antihypertensive agent
within Veterans Affairs primary care clinics. Most of the
135 providers classified as clinical inertia indicated ‘con-
tinue current medications and I will discuss at the next
visit’ [33]. Waiting for another visit is also frequent for
uncontrolled patients in Spain [34]. It is possible that
physicians who did not give a reason for the clinical inertia
in our study were also adopting a ‘wait and see’ approach.
Limitations of our study are those related to the cross-
sectional design, i.e. lack of follow-up. Regarding the
patient selection process, physicians were asked to select
their own cases of clinical inertia and this fact could
introduce some bias; however, patients were included by
consecutive sampling as they came to the office, and this
method is commonly used in hypertension research.
The data reporting physicians’ reasons to justify clinical
inertia included the answer ‘No reason to give’, which was
made by proactively selecting a mark in the survey tool, so
this could not be a ‘lost case’ or a failed response.
In order to minimize measurement bias, we followed
recommendations from previously published studies [12–
14], although it must be taken into account that having dif-
ferent devices to measure BP could itself introduce bias.
Otherwise, for clinical inertia studies, the aim is focused
more on the interpretation and attitude of physicians than on
the validity of BP measure. Even so, physicians in our study
were informed of the possibility that a reason for clinical
inertia may be the inability to rule out an incorrect BP
measurement. However, the prevalence of this reason was
very low, and was included in ‘other reasons’ in our analysis.
Strengths of our study include the following: we were
able to analyze several factors and reasons at the same
time; and the proportion of losses was very low (1 %),
probably because we used a short electronic data collection
sheet that was easy for the physician to complete [15]. This
also facilitated the real-time transmission of information
from the office for analysis, thereby improving the quality
of data collected; confounding factors were controlled
using a physician-adjusted multivariate analysis.
In conclusion, physicians gave reasons for clinical inertia in
only one of three aged hypertensive patients. The main rea-
sons were borderline BP values, patient difficult to manage,
white coat effect suspected, or difficult to achieve target BP
goal. It is necessary to discuss guideline-recommended targets
in elderly hypertensive patients with clinicians.
Acknowledgments The authors wish to thank all the physicians of
the INERCAP study and the SEH-LELHA compliance group and
Almirall S. A., for its unrestricted grant.
Conflicts of interest The authors state no conflict of interest.
References
1. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR,
Grimm RH, et al. ALLHAT Collaborative Research Group.
Success and predictors of blood pressure control in diverse North
American settings: the antihypertensive and lipid-lowering
treatment to prevent heart attack trial (ALLHAT). J Clin Hy-
pertens (Greenwich). 2002; 4(6):393–404.
2. SHEP Cooperative Research Group. Prevention of stroke by
antihypertensive drug treatment in older persons with isolated
systolic hyertension: final results of the systolic hypertension in
the elderly program (SHEP). JAMA. 1991;265:3255–64.
218 V. Gil-Guille´n et al.
Author's personal copy
3. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Bir-
kenha¨ger WH, et al. Randomised double-blind comparison of
placebo and active treatment for older patients with isolated
systolic hypertension. The Systolic Hypertension in Europe (Syst-
Eur) Trial Investigators. Lancet. 1997;350(9080):757–64.
4. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM,
Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135(9):
825–34.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA,
Izzo JL Jr, et al. Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure.
National Heart, Lung, and Blood Institute; National High Blood
Pressure Education Program Coordinating Committee. Seventh
report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure. Hypertension.
2003;42(6):1206–52.
6. Phillips LS, Twombly JG. It’s time to overcome clinical inertia.
Ann Intern Med. 2008;148(10):783–5.
7. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL,
Egan BM. Therapeutic inertia is an impediment to achieving the
Healthy People 2010 blood pressure control goals. Hypertension.
2006;47(3):345–51.
8. O’Connor PJ, Sperl-Hillen JAM, Johnson PE, Rush WA, Biltz G.
Clinical inertia and outpatient medical errors. In: Henriksen K,
Battles JB, Marks ES, Lewin DI, editors. Advances in patient
safety: from research to implementation (vol. 2: concepts and
methodology). Rockville (MD): Agency for Healthcare Research
and Quality; 2005.
9. Redo´n J, Coca A, La´zaro P, Aguilar MD, Caban˜as M, Gil N,
Sa´nchez-Zamorano MA, Aranda P. Factors associated with
therapeutic inertia in hypertension: validation of a predictive
model. J Hypertens. 2010;28(8):1770–7.
10. Gil-Guille´n V, Orozco-Beltra´n D, Pe´rez RP, Alfonso JL, Redo´n J,
Pertusa-Martı´nez S, et al. Clinical inertia in diagnosis and treat-
ment of hypertension in primary care: quantification and associ-
ated factors. Blood Press. 2010;19(1):3–10.
11. Ferrari P, Hess L, Pechere-Bertschi A, Muggli F, Burnier M.
Reasons for not intensifying antihypertensive treatment (RIAT): a
primary care antihypertensive intervention study. J Hypertens.
2004;22(6):1221–9.
12. Oliveria SA, Lapuerta P, McCarthy BD, L’Italien GJ, Berlowitz
DR, Asch SM. Physician-related barriers to the effective man-
agement of uncontrolled hypertension. Arch Intern Med.
2002;162(4):413–20.
13. Ferrari P; National Coordinators for the Reasons for not Intensi-
fying Antihypertensive Treatment (RIAT) trial12. Reasons for
therapeutic inertia when managing hypertension in clinical practice
in non-Western countries. J Hum Hypertens. 2009; 23(3):151–9.
14. Ma´rquez-Contreras E, Coca A, de la Figuera von Wichmann M,
Diviso´n JA, Llisterri JL, Sobrino J, Control-Project Researchers,
et al. Cardiovascular risk profile of uncontrolled hypertensive
patients. The Control-Project study (in Spanish). Med Clin
(Barc). 2007;128(3):86–91.
15. Gil-Guille´n V, Orozco-Beltra´n D, Ma´rquez-Contreras E, Durazo-
Arvizu R, Cooper R, Pita-Ferna´ndez S, et al. Is there a predictive
profile for clinical inertia in hypertensive patients? An observational,
cross-sectional, multicentre study. Drugs Aging. 2011;28(12):981–92.
16. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R,
Germano G, Management of Arterial Hypertension of the Euro-
pean Society of Hypertension, European Society of Cardiology,
et al. 2007 guidelines for the management of arterial hyperten-
sion: the Task Force for the Management of Arterial Hyperten-
sion of the European Society of Hypertension (ESH) and of the
European Society of Cardiology (ESC) (published erratum
appears in J Hypertens. 2007 Aug; 25(8):1749). J Hypertens.
2007;25(6):1105–87.
17. O’Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G,
European Society of Hypertension Working Group on Blood
Pressure Monitoring, et al. European Society of Hypertension
recommendations for conventional, ambulatory and home blood
pressure measurement. J Hypertens. 2003;21(5):821–48.
18. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M,
Caulfield MJ, et al. Reappraisal of European guidelines on
hypertension management: a European Society of Hypertension
Task Force document. J Hypertens. 2009;27(11):2121–58.
19. Crescioni M, Gorina Y, Bilheimer L, Gillum RF. Trends in health
status and health care use among older men. Natl Health Stat
Report. 2010;24:1–18.
20. Wong ND, Lopez VA, L’Italien G, Chen R, Kline SE, Franklin
SS. Inadequate control of hypertension in US adults with car-
diovascular disease comorbidities in 2003–2004. Arch Intern
Med. 2007;167(22):2431–6.
21. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A,
Brunner HR, et al. The Valsartan antihypertensive long-term use
evaluation (VALUE) trial: outcomes in patients receiving
monotherapy. Hypertension. 2006;48(3):385–91.
22. Nasser SA, Lai Z, O’Connor S, Liu X, Flack JM. Does earlier
attainment of blood pressure goal translate into fewer cardio-
vascular events? Curr Hypertens Rep. 2008; 10(5):398–404.
23. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu
D, HYVET Study Group, et al. Treatment of hypertension in patients
80 years of age or older. N Engl J Med. 2008;358(18):1887–98.
24. Milani RV. Reaching for aggressive blood pressure goals: role of
angiotensin receptor blockade in combination therapy. Am J
Manag Care. 2005;11(7 Suppl):S220–7.
25. Jamerson K, Weber MA, Bakris GL, Dahlo¨f B, Pitt B, Shi V,
ACCOMPLISH trial investigators, et al. Benazepril plus amlo-
dipine or hydrochlorothiazide for hypertension in high-risk
patients. N Engl J Med. 2008;359(23):2417–28.
26. Ho PM, Magid DJ, Shetterly SM, Olson KL, Peterson PN, Masoudi
FA, Rumsfeld JS. Importance of therapy intensification and med-
ication non-adherence for blood pressure control in patients with
coronary disease. Arch Intern Med. 2008;168(3):271–6.
27. Gorostidi M, Sobrino J, Segura J, Sierra C, de la Sierra A, Her-
na´ndez del Rey R, Spanish Society of Hypertension ABPM
Registry investigators, et al. Ambulatory blood pressure moni-
toring in hypertensive patients with high cardiovascular risk: a
cross-sectional analysis of a 20,000-patient database in Spain.
J Hypertens. 2007;25(5):977–84.
28. Hyman DJ, Pavlik VN, Vallbona C. Physician role in lack of
awareness and control of hypertension. J Clin Hypertens
(Greenwich). 2000;2(5):324–30.
29. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M,
Kader B, Moskowitz MA. Inadequate management of blood pressure
in a hypertensive population. N Engl J Med. 1998;339(27):1957–63.
30. Federal Interagency Forum on Aging-Related Statistics. Older
Americans 2010. Key indicators of well-being: federal inter-
agency forum on aging-related statistics. Washington DC: US
Government Printing Office; 2010.
31. el-Kebbi IM, Ziemer DC, Gallina DL, Dunbar V, Phillips LS.
Diabetes in urban African–Americans. XV. Identification of
barriers to provider adherence to management protocols. Diabetes
Care. 1999; 22(10):1617–20.
32. Ogedegbe G. Barriers to optimal hypertension control. J Clin
Hypertens (Greenwich). 2008;10(8):644–6.
33. Roumie CL, Elasy TA, Wallston KA, Pratt S, Greevy RA, Liu X,
et al. Clinical inertia: a common barrier to changing provider
prescribing behavior. Jt Comm J Qual Patient Saf.
2007;33(5):277–85.
34. Ortiz Tobarra MT, Orozco Beltra´n D, Gil Guille´n V, Terol Molto´
C. Frequency of attendance and degree of control of type-2 dia-
betic patients (in Spanish). Aten Primaria. 2008; 40(3):139–44.
Clinical Inertia in Treating Hypertension 219
